Robbins; Michael Darron
Patent Applications and Registrations
Patent applications and USPTO patent grants for Robbins; Michael Darron.The latest application filed is for "immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer".
- Robbins; Michael Darron - Lebanon NJ
- Robbins; Michael Darron - Hillsborough NJ
- ROBBINS; Michael Darron - Whitehouse Station NJ
| Patent | Date |
|---|---|
| Immunotherapeutic Dosing Regimens Comprising Pomalidomide And An Anti-cs1 Antibody For Treating Cancer App 20210154183 - Mulligan; Christopher Lee ; et al. | 2021-05-27 |
| Immunotherapeutic dosing regimens comprising pomalidomide and an anti-CS1 antibody for treating cancer Grant 10,925,867 - Mulligan , et al. February 23, 2 | 2021-02-23 |
| Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma Grant 10,494,433 - Andre , et al. De | 2019-12-03 |
| Immunotherapeutic Dosing Regimens Comprising Pomalidomide And An Anti-cs1 Antibody For Treating Cancer App 20180185348 - MULLIGAN; Christopher Lee ; et al. | 2018-07-05 |
| Combination Of Anti-cs1 And Anti-pd1 Antibodies To Treat Cancer (myeloma) App 20170355768 - ROBBINS; Michael Darron ; et al. | 2017-12-14 |
| Immunotherapeutic Dosing Regimens And Combinations Thereof App 20160264670 - Graziano; Robert F ; et al. | 2016-09-15 |
| Combination Of Anti-kir And Anti-cs1 Antibodies To Treat Multiple Myeloma App 20160257750 - ANDRE; Pascale ; et al. | 2016-09-08 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 